One Wealth Advisors LLC Invests $827,000 in Edwards Lifesciences Corporation $EW

One Wealth Advisors LLC bought a new position in Edwards Lifesciences Corporation (NYSE:EW) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 9,145 shares of the medical research company’s stock, valued at approximately $827,000.

A number of other institutional investors have also recently bought and sold shares of EW. Maridea Wealth Management LLC purchased a new stake in Edwards Lifesciences in the second quarter valued at approximately $2,052,000. Bank Hapoalim BM purchased a new position in Edwards Lifesciences during the second quarter worth approximately $1,777,000. BIP Wealth LLC purchased a new position in Edwards Lifesciences during the second quarter worth approximately $208,000. Trifecta Capital Advisors LLC acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $394,000. Finally, Everett Harris & Co. CA acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $7,268,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

EW has been the subject of a number of research analyst reports. JPMorgan Chase & Co. upped their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “overweight” rating in a report on Friday, July 24th. UBS Group assumed coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They issued a “buy” rating and a $110.00 target price on the stock. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $87.00 to $101.00 in a research report on Friday, July 24th. Wall Street Zen downgraded Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Finally, TD Cowen restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday, July 21st. Seventeen investment analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 620 shares of the company’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $81.14, for a total value of $50,306.80. Following the completion of the sale, the vice president owned 40,411 shares of the company’s stock, valued at $3,278,948.54. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the stock in a transaction dated Friday, May 29th. The shares were sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president owned 15,334 shares of the company’s stock, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 26,190 shares of company stock valued at $2,269,697 over the last three months. 0.31% of the stock is owned by company insiders.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock opened at $91.51 on Friday. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29. The firm has a fifty day moving average of $88.73 and a 200-day moving average of $84.37. The firm has a market capitalization of $52.69 billion, a P/E ratio of 52.59, a PEG ratio of 2.30 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating analysts’ consensus estimates of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The business had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.